T Regulatory Cells in Allergen-Specific Immunotherapy

A dramatic increase in the prevalence of allergy and asthma has occurred during the past few decades. Although the symptoms of many allergic disorders can be suppressed quite effectively by pharmacological interventions, these do not provide a curative solution and therefore involve lifelong use of medication. Allergen-specific immunotherapy (SIT) on the other hand provides a long-lasting effect on the immune response to common environmental antigens, therefore allowing cessation of the therapy after several years. The changes in the immune response brought about by allergen-SIT are slowly being unveiled and explained. Mechanisms underlying allergen-SIT and in particular the role of regulatory T cells will be discussed in this review, based on recent findings and current concepts.

[1]  C. Akdis.  Allergy and hypersensitivity: mechanisms of allergic disease. , 2006, Current opinion in immunology.

[2]  C. Akdis,et al.  Immunological mechanisms of allergen-specific immunotherapy , 2006, Nature Reviews Immunology.

[3]  L. Håkansson,et al.  Production of interleukin-12 by monocytes and interferon-gamma by natural killer cells in allergic patients during rush immunotherapy. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  A. Burks,et al.  The Major Glycoprotein Allergen from Arachis hypogaea, Ara h 1, Is a Ligand of Dendritic Cell-Specific ICAM-Grabbing Nonintegrin and Acts as a Th2 Adjuvant In Vitro1 , 2006, The Journal of Immunology.

[5]  Katharina Fleischhauer,et al.  Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans , 2006, Immunological reviews.

[6]  E. Knol,et al.  Requirements for effective IgE cross-linking on mast cells and basophils. , 2006, Molecular nutrition & food research.

[7]  A. Magnan,et al.  Ultra‐rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  B. Harder,et al.  IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[9]  D. Robinson,et al.  Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent , 2005, The Journal of experimental medicine.

[10]  T. Chatila.  Role of regulatory T cells in human diseases. , 2005, The Journal of allergy and clinical immunology.

[11]  T. Geiger,et al.  IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Y. Groner,et al.  Accelerated chemokine receptor 7-mediated dendritic cell migration in Runx3 knockout mice and the spontaneous development of asthma-like disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Pladevall,et al.  Timing and intensity of early fevers and the development of allergies and asthma. , 2005, The Journal of allergy and clinical immunology.

[14]  Sharon Hensley Alford,et al.  Antibiotic exposure in early infancy and risk for childhood atopy. , 2005, The Journal of allergy and clinical immunology.

[15]  Dexiang Chen,et al.  Peptide induces CD4(+)CD25+ and IL-10+ T cells and protection in airway allergy models. , 2005, Vaccine.

[16]  T. Beaty,et al.  Genetic variants of the T-cell immunoglobulin mucin 1 but not the T-cell immunoglobulin mucin 3 gene are associated with asthma in an African American population. , 2005, The Journal of allergy and clinical immunology.

[17]  L. Chatenoud,et al.  Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. , 2005, Diabetes.

[18]  J. Ioannidis,et al.  Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. , 2005, The Journal of allergy and clinical immunology.

[19]  A. Rudensky,et al.  TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells , 2005, The Journal of experimental medicine.

[20]  D. Wraith,et al.  Peptide-based therapeutic vaccines for allergic and autoimmune diseases , 2005, Nature Medicine.

[21]  R. Fimmers,et al.  Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. , 2005, The Journal of allergy and clinical immunology.

[22]  Andrew Saxon,et al.  Air pollution and allergy: you are what you breathe , 2005, Nature Immunology.

[23]  O. Migita,et al.  Association of a haplotype block spanning SDAD1 gene and CXC chemokine genes with allergic rhinitis. , 2005, The Journal of allergy and clinical immunology.

[24]  J. Pekkanen,et al.  Allergen‐specific sensitization in asthma and allergic diseases in children: the study on farmers' and non‐farmers' children , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  C. Akdis,et al.  A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. , 2005, The Journal of allergy and clinical immunology.

[26]  M. Blennerhassett,et al.  The increasing prevalence of Crohn's disease in industrialized societies: the price of progress? , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[27]  S. Burdach,et al.  Reduced expression of transforming growth factor β1 exacerbates pathology in an experimental asthma model , 2005, European journal of immunology.

[28]  M. Neurath,et al.  Cutting Edge: TGF-β Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells1 , 2004, The Journal of Immunology.

[29]  C. Akdis,et al.  Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. , 2004, The Journal of allergy and clinical immunology.

[30]  C. Suphioglu,et al.  Hypoallergenic Variants of the Major Latex Allergen Hev b 6.01 Retaining Human T Lymphocyte Reactivity1 , 2004, The Journal of Immunology.

[31]  D. Postma,et al.  Childhood factors associated with asthma remission after 30 year follow up , 2004, Thorax.

[32]  A. Kay,et al.  Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled study , 2004, Allergy.

[33]  R. Valenta,et al.  Non‐anaphylactic surface‐exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[34]  T. Bieber,et al.  Transforming Growth Factor-β1 Regulates the Expression of the High-Affinity Receptor for IgE on CD34+ Stem Cell-Derived CD1a+ Dendritic Cells In Vitro , 2004 .

[35]  J. Roes,et al.  TGF-β Receptor Signaling Is Critical for Mucosal IgA Responses1 , 2004, The Journal of Immunology.

[36]  P. Eigenmann,et al.  Antigen-specific secretory IgA antibodies in the gut are decreased in a mouse model of food allergy. , 2004, The Journal of allergy and clinical immunology.

[37]  S. Durham,et al.  Mechanisms of immunotherapy: IgG revisited , 2004, Current opinion in allergy and clinical immunology.

[38]  D. Leung,et al.  Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists. , 2004, The Journal of allergy and clinical immunology.

[39]  Scott R. Presnell,et al.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice , 2004, Nature Immunology.

[40]  M. Karlsson,et al.  Allergen-responsive CD4+CD25+ Regulatory T Cells in Children who Have Outgrown Cow's Milk Allergy , 2004, The Journal of experimental medicine.

[41]  C. Akdis,et al.  Immune Responses in Healthy and Allergic Individuals Are Characterized by a Fine Balance between Allergen-specific T Regulatory 1 and T Helper 2 Cells , 2004, The Journal of experimental medicine.

[42]  G. Liss,et al.  Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. , 2004, The Journal of allergy and clinical immunology.

[43]  S. Durham,et al.  Mechanisms of immunotherapy. , 2004, The Journal of allergy and clinical immunology.

[44]  C. Berry,et al.  Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Dallman,et al.  Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease , 2004, The Lancet.

[46]  J. Rolland,et al.  High Dose Allergen Stimulation of T Cells from House Dust Mite-Allergic Subjects Induces Expansion of IFN-γ+ T Cells, Apoptosis of CD4+IL-4+ T Cells and T Cell Anergy , 2004, International Archives of Allergy and Immunology.

[47]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[48]  G. Girolomoni,et al.  Human CD25+ Regulatory T Cells Maintain Immune Tolerance to Nickel in Healthy, Nonallergic Individuals 1 , 2003, The Journal of Immunology.

[49]  W. Leitner,et al.  DNA vaccines for non-infectious diseases: new treatments for tumour and allergy , 2003, Expert opinion on biological therapy.

[50]  Jean Paul Remon,et al.  Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 , 2003, Nature Biotechnology.

[51]  C. Akdis,et al.  Histamine in the immune regulation of allergic inflammation. , 2003, The Journal of allergy and clinical immunology.

[52]  T. Bieber,et al.  Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. , 2003, The Journal of allergy and clinical immunology.

[53]  S. Durham,et al.  Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. , 2003, The Journal of allergy and clinical immunology.

[54]  M. Akdiş,et al.  Histamine enhances TGF‐β1‐mediated suppression of Th2 responses , 2003 .

[55]  Marek Jutel,et al.  IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy , 2003, European journal of immunology.

[56]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[57]  K. Min,et al.  Allergen‐specific conventional immunotherapy decreases immunoglobulin E‐mediated basophil histamine releasability , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[58]  E. Gale.  The rise of childhood type 1 diabetes in the 20th century. , 2002, Diabetes.

[59]  J. Benovic.  Novel β2-adrenergic receptor signaling pathways , 2002 .

[60]  David F. Richards,et al.  In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.

[61]  P. Hellings,et al.  Blockade of CTLA‐4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice , 2002, European journal of immunology.

[62]  H. Young,et al.  Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. , 2001, The Journal of clinical investigation.

[63]  J. Bonnefoy,et al.  Histamine Polarizes Human Dendritic Cells into Th2 Cell-Promoting Effector Dendritic Cells , 2001, The Journal of Immunology.

[64]  Marek Jutel,et al.  Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors , 2001, Nature.

[65]  R. de Waal Malefyt,et al.  IFN-α and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells1 , 2001, The Journal of Immunology.

[66]  T. Platts-Mills,et al.  Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study , 2001, The Lancet.

[67]  A. Bowcock,et al.  JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. , 2000, The Journal of clinical investigation.

[68]  M. Luqman,et al.  Antigen-specific T cell tolerance down-regulates mast cell responses in vivo. , 2000, Cellular immunology.

[69]  C. Akdis,et al.  A molecular basis for T cell suppression by IL‐10: CD28‐associated IL‐10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3‐kinase binding , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  D. Lebman,et al.  The role of TGF-β in growth, differentiation, and maturation of B lymphocytes , 1999 .

[71]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.

[72]  C. Akdis,et al.  Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. , 1998, The Journal of allergy and clinical immunology.

[73]  Hervé Groux,et al.  A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.

[74]  H. Savelkoul,et al.  T cells subsets and cytokines in allergic and non-allergic children. II. Analysis and IL-5 and IL-10 mRNA expression and protein production. , 1997, Cytokine.

[75]  C. Akdis,et al.  Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. , 1996, The Journal of clinical investigation.

[76]  S. Wenzel,et al.  Interleukin-10 regulation in normal subjects and patients with asthma. , 1996, The Journal of allergy and clinical immunology.

[77]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[78]  H. Weiner,et al.  Oral tolerance , 2011, Immunological reviews.

[79]  M. Goldman,et al.  B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. , 1994, Journal of immunology.

[80]  J. Virchow,et al.  T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. , 1991, Journal of immunology.

[81]  P. Venge,et al.  Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. , 1990, The Journal of allergy and clinical immunology.

[82]  L. Lichtenstein,et al.  Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids. , 1989, Journal of immunology.

[83]  G. Gleich,et al.  Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. , 1982, The Journal of allergy and clinical immunology.

[84]  P. Schmid‐Grendelmeier,et al.  Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. , 2006, Journal of investigational allergology & clinical immunology.

[85]  M. Akdiş,et al.  Histamine enhances TGF-beta1-mediated suppression of Th2 responses. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[86]  N. Osna,et al.  Regulation of interleukin-10 secretion by histamine in TH2 cells and splenocytes. , 2001, International immunopharmacology.

[87]  R. de Waal Malefyt,et al.  IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. , 2001, Journal of immunology.